Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
June 21 2024 - 1:21PM
Business Wire
Wall Street Beats is pleased to announce an investor conference
call with Doug Ingram, CEO of Sarepta Therapeutics, following the
landmark FDA approval expanding the label for ELEVIDYS
(delandistrogene moxeparvovec-rokl) to treat Duchenne muscular
dystrophy (DMD) patients aged four and above. The call will be
hosted by David Maris, a six-time #1 ranked pharma analyst and
partner at Wall Street Beats.
Maris stated, "Sarepta's expanded label approval for ELEVIDYS is
a landmark achievement that underscores Sarepta's relentless
pursuit of solutions for the Duchenne community and the
transformative potential of gene therapy. This is an exciting
opportunity to host Sarepta's CEO, Doug Ingram, and hear more about
Sarepta's long-term strategic vision and the significant milestone
this approval represents."
Key Points:
- Ground-Breaking Advance for Patients: The expanded label
includes both ambulatory and non-ambulatory DMD patients,
representing a significant milestone in gene therapy and patient
care.
- Strategic Insights: This call aims to delve deeper into
Sarepta's longer-term goals and strategic initiatives.
- Landmark Approval: This approval marks a watershed
moment for the Duchenne community and the promise of gene
therapy.
Event Details:
- Date: June 21, 2024
- Time: 2:00 p.m. ET/11:00 a.m. PT
- Webcast: https://wallstreetbeats.com/interview
Join us to gain deeper understanding and insights directly from
Sarepta's leadership on this pivotal development.
Users can sign up for a 24-hour preview to access the
interview.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240621789839/en/
Steven Lamar steven@wallstreetbeats.com